Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapy
{{output}}
Purpose: Chimeric antigen receptor T-cell (CART) therapy targeting CD19 is effective for relapsed/refractory (r/r) lymphoma. As part of the lymphatic system, the spleen might influence CART outcomes. We examined how spleen volume... ...
